HPHA Stock Overview
A biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Heidelberg Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.17 |
| 52 Week High | €4.07 |
| 52 Week Low | €2.18 |
| Beta | -0.36 |
| 11 Month Change | -18.73% |
| 3 Month Change | -9.96% |
| 1 Year Change | -22.22% |
| 33 Year Change | -61.86% |
| 5 Year Change | -1.81% |
| Change since IPO | -95.90% |
Recent News & Updates
Recent updates
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
Feb 16
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Dec 05Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Jul 21Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Oct 16Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Nov 28Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
Mar 27We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Mar 15Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Jan 17
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Dec 14Shareholder Returns
| HPHA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.3% | 0.8% | -0.4% |
| 1Y | -22.2% | -16.7% | 7.1% |
Return vs Industry: HPHA underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: HPHA underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| HPHA volatility | |
|---|---|
| HPHA Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HPHA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: HPHA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 98 | Andreas Pahl | heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors.
Heidelberg Pharma AG Fundamentals Summary
| HPHA fundamental statistics | |
|---|---|
| Market cap | €104.40m |
| Earnings (TTM) | -€18.77m |
| Revenue (TTM) | €8.47m |
11.9x
P/S Ratio-5.4x
P/E RatioIs HPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HPHA income statement (TTM) | |
|---|---|
| Revenue | €8.47m |
| Cost of Revenue | €1.66m |
| Gross Profit | €6.81m |
| Other Expenses | €25.58m |
| Earnings | -€18.77m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 80.41% |
| Net Profit Margin | -221.51% |
| Debt/Equity Ratio | 0% |
How did HPHA perform over the long term?
See historical performance and comparison